YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway

S. Y. Wu, S. L. Pan, T. H. Chen, C. H. Liao, D. Y. Huang, J. H. Guh, Y. L. Chang, S. C. Kuo, F. Y. Lee, C. M. Teng

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background and purpose: The aim of this study was to elucidate the mechanism of YC-1{3-(5′-hydroxy methyl-2′-furyl)-1-benzylindazole}- induced human renal carcinoma cells apoptosis and to evaluate the potency of YC-1 in models of tumour growth in mice. Experimental approach: YC-1-mediated apoptosis was assessed by analysis of MTT, SRB, DAPI staining and flow cytometry analysis. Knockdown of JNK protein was achieved by transient transfection using siRNA. The mechanisms of action of YC-1 on different signalling pathways involved were studied using western blot. Fas clustering was analysed by confocal microscopy and in vivo efficacy was examined in a A498 xenograft model. Key results: YC-1 displayed cytotoxicity in renal carcinoma cells at 10 -7-10 -8 M. Increased condensation of chromatin was observed and an increase in the cell population in subG1 phase. Moreover, YC-1 triggered mitochondria-mediated and caspase-dependent pathways. YC-1 significantly induced Fas ligand expression, but did not modify either the protein levels of death receptors or ligands. In addition, Fas clustering in cells responsive to YC-1 was observed, suggesting involvement of a Fas-mediated pathway. Furthermore, YC-1 markedly induced phosphorylation of JNK and a JNK inhibitor, SP600125, and siRNA JNK1/2 significantly reversed YC-1-induced cytotoxicity and protein expression. We suggest that YC-1 induced JNK phosphorylation, the upregulation of FasL and Fas receptor clustering to promote the activation of caspases 8 and 3, resulting in apoptosis. Finally, we demonstrated the antitumour effect of YC-1 in vivo. Conclusions and implications: These data suggest that YC-1 is a good candidate for development as an anticancer drug.

Original languageEnglish
Pages (from-to)505-513
Number of pages9
JournalBritish Journal of Pharmacology
Volume155
Issue number4
DOIs
Publication statusPublished - Oct 2008
Externally publishedYes

Fingerprint

MAP Kinase Signaling System
Renal Cell Carcinoma
Cluster Analysis
Apoptosis
Small Interfering RNA
Phosphorylation
CD95 Antigens
Death Domain Receptors
Proteins
Fas Ligand Protein
Caspase 8
Caspases
Heterografts
Confocal Microscopy
Caspase 3
Chromatin
Transfection
Flow Cytometry
Mitochondria
Up-Regulation

Keywords

  • Apoptosis
  • JNK
  • Renal cancer
  • YC-1

ASJC Scopus subject areas

  • Pharmacology

Cite this

YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway. / Wu, S. Y.; Pan, S. L.; Chen, T. H.; Liao, C. H.; Huang, D. Y.; Guh, J. H.; Chang, Y. L.; Kuo, S. C.; Lee, F. Y.; Teng, C. M.

In: British Journal of Pharmacology, Vol. 155, No. 4, 10.2008, p. 505-513.

Research output: Contribution to journalArticle

Wu, SY, Pan, SL, Chen, TH, Liao, CH, Huang, DY, Guh, JH, Chang, YL, Kuo, SC, Lee, FY & Teng, CM 2008, 'YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway', British Journal of Pharmacology, vol. 155, no. 4, pp. 505-513. https://doi.org/10.1038/bjp.2008.292
Wu, S. Y. ; Pan, S. L. ; Chen, T. H. ; Liao, C. H. ; Huang, D. Y. ; Guh, J. H. ; Chang, Y. L. ; Kuo, S. C. ; Lee, F. Y. ; Teng, C. M. / YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway. In: British Journal of Pharmacology. 2008 ; Vol. 155, No. 4. pp. 505-513.
@article{c229041be5794570844f6212ea31cd40,
title = "YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway",
abstract = "Background and purpose: The aim of this study was to elucidate the mechanism of YC-1{3-(5′-hydroxy methyl-2′-furyl)-1-benzylindazole}- induced human renal carcinoma cells apoptosis and to evaluate the potency of YC-1 in models of tumour growth in mice. Experimental approach: YC-1-mediated apoptosis was assessed by analysis of MTT, SRB, DAPI staining and flow cytometry analysis. Knockdown of JNK protein was achieved by transient transfection using siRNA. The mechanisms of action of YC-1 on different signalling pathways involved were studied using western blot. Fas clustering was analysed by confocal microscopy and in vivo efficacy was examined in a A498 xenograft model. Key results: YC-1 displayed cytotoxicity in renal carcinoma cells at 10 -7-10 -8 M. Increased condensation of chromatin was observed and an increase in the cell population in subG1 phase. Moreover, YC-1 triggered mitochondria-mediated and caspase-dependent pathways. YC-1 significantly induced Fas ligand expression, but did not modify either the protein levels of death receptors or ligands. In addition, Fas clustering in cells responsive to YC-1 was observed, suggesting involvement of a Fas-mediated pathway. Furthermore, YC-1 markedly induced phosphorylation of JNK and a JNK inhibitor, SP600125, and siRNA JNK1/2 significantly reversed YC-1-induced cytotoxicity and protein expression. We suggest that YC-1 induced JNK phosphorylation, the upregulation of FasL and Fas receptor clustering to promote the activation of caspases 8 and 3, resulting in apoptosis. Finally, we demonstrated the antitumour effect of YC-1 in vivo. Conclusions and implications: These data suggest that YC-1 is a good candidate for development as an anticancer drug.",
keywords = "Apoptosis, JNK, Renal cancer, YC-1",
author = "Wu, {S. Y.} and Pan, {S. L.} and Chen, {T. H.} and Liao, {C. H.} and Huang, {D. Y.} and Guh, {J. H.} and Chang, {Y. L.} and Kuo, {S. C.} and Lee, {F. Y.} and Teng, {C. M.}",
year = "2008",
month = "10",
doi = "10.1038/bjp.2008.292",
language = "English",
volume = "155",
pages = "505--513",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway

AU - Wu, S. Y.

AU - Pan, S. L.

AU - Chen, T. H.

AU - Liao, C. H.

AU - Huang, D. Y.

AU - Guh, J. H.

AU - Chang, Y. L.

AU - Kuo, S. C.

AU - Lee, F. Y.

AU - Teng, C. M.

PY - 2008/10

Y1 - 2008/10

N2 - Background and purpose: The aim of this study was to elucidate the mechanism of YC-1{3-(5′-hydroxy methyl-2′-furyl)-1-benzylindazole}- induced human renal carcinoma cells apoptosis and to evaluate the potency of YC-1 in models of tumour growth in mice. Experimental approach: YC-1-mediated apoptosis was assessed by analysis of MTT, SRB, DAPI staining and flow cytometry analysis. Knockdown of JNK protein was achieved by transient transfection using siRNA. The mechanisms of action of YC-1 on different signalling pathways involved were studied using western blot. Fas clustering was analysed by confocal microscopy and in vivo efficacy was examined in a A498 xenograft model. Key results: YC-1 displayed cytotoxicity in renal carcinoma cells at 10 -7-10 -8 M. Increased condensation of chromatin was observed and an increase in the cell population in subG1 phase. Moreover, YC-1 triggered mitochondria-mediated and caspase-dependent pathways. YC-1 significantly induced Fas ligand expression, but did not modify either the protein levels of death receptors or ligands. In addition, Fas clustering in cells responsive to YC-1 was observed, suggesting involvement of a Fas-mediated pathway. Furthermore, YC-1 markedly induced phosphorylation of JNK and a JNK inhibitor, SP600125, and siRNA JNK1/2 significantly reversed YC-1-induced cytotoxicity and protein expression. We suggest that YC-1 induced JNK phosphorylation, the upregulation of FasL and Fas receptor clustering to promote the activation of caspases 8 and 3, resulting in apoptosis. Finally, we demonstrated the antitumour effect of YC-1 in vivo. Conclusions and implications: These data suggest that YC-1 is a good candidate for development as an anticancer drug.

AB - Background and purpose: The aim of this study was to elucidate the mechanism of YC-1{3-(5′-hydroxy methyl-2′-furyl)-1-benzylindazole}- induced human renal carcinoma cells apoptosis and to evaluate the potency of YC-1 in models of tumour growth in mice. Experimental approach: YC-1-mediated apoptosis was assessed by analysis of MTT, SRB, DAPI staining and flow cytometry analysis. Knockdown of JNK protein was achieved by transient transfection using siRNA. The mechanisms of action of YC-1 on different signalling pathways involved were studied using western blot. Fas clustering was analysed by confocal microscopy and in vivo efficacy was examined in a A498 xenograft model. Key results: YC-1 displayed cytotoxicity in renal carcinoma cells at 10 -7-10 -8 M. Increased condensation of chromatin was observed and an increase in the cell population in subG1 phase. Moreover, YC-1 triggered mitochondria-mediated and caspase-dependent pathways. YC-1 significantly induced Fas ligand expression, but did not modify either the protein levels of death receptors or ligands. In addition, Fas clustering in cells responsive to YC-1 was observed, suggesting involvement of a Fas-mediated pathway. Furthermore, YC-1 markedly induced phosphorylation of JNK and a JNK inhibitor, SP600125, and siRNA JNK1/2 significantly reversed YC-1-induced cytotoxicity and protein expression. We suggest that YC-1 induced JNK phosphorylation, the upregulation of FasL and Fas receptor clustering to promote the activation of caspases 8 and 3, resulting in apoptosis. Finally, we demonstrated the antitumour effect of YC-1 in vivo. Conclusions and implications: These data suggest that YC-1 is a good candidate for development as an anticancer drug.

KW - Apoptosis

KW - JNK

KW - Renal cancer

KW - YC-1

UR - http://www.scopus.com/inward/record.url?scp=53849131648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53849131648&partnerID=8YFLogxK

U2 - 10.1038/bjp.2008.292

DO - 10.1038/bjp.2008.292

M3 - Article

C2 - 18641674

AN - SCOPUS:53849131648

VL - 155

SP - 505

EP - 513

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 4

ER -